Matthew E. Lipman - 14 Feb 2025 Form 3 Insider Report for Capstone Holding Corp. (CAPS)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Matthew E. Lipman
Issuer symbol: CAPS
Transactions as of: 14 Feb 2025
Net transactions value: $0
Form type: 3
Filing time: 22 Apr 2025, 15:53:49 UTC
Previous filing: 10 Dec 2024
Next filing: 03 Jun 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CAPS	Common Stock						2,650,436	14 Feb 2025	See Footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CAPS	Common Stock Warrants							14 Feb 2025	Common Stock	6,322	$75.00	See Footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of (i) 121,774 shares controlled by Matthew Lipman, through his control of BP Peptides, LLC. Brookstone Acquisition Partners XXI Corporation owns 81% of BP Peptides, LLC. Mr. Lipman owns approximately 4% of Brookstone Acquisition Partners XXI Corporation; and (ii) 2,528,662 shares of Common Stock owned by BPA XIV, LLC, an entity controlled by Matthew Lipman.
F2	Includes a warrant to purchase up to 6,322 shares of Common Stock issued to Brookstone Partners IAC, Inc., the investment manager of BP Peptides, LLC which is controlled by Matthew Lipman and Michael Toporek.